^
Association details:
| Biomarker: | HRAS G12V |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition
Excerpt:
...Treatment of mice with HrasG12V/Nf2-null thyroid cancers with AZD6244 resulted in a greater and more consistent reduction of tumor size than in cancers arising in HrasG12V/Pten-null or HrasG12V/Trp53-null mice…
DOI:
10.1158/2159-8290.CD-15-0330
